We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Teva has denied allegations from the European Commission (EC) that it engaged in illegal anti-competitive pay-to-delay tactics to maintain its market share in the sleep disorder drug space at a hearing this week, it has emerged.